### About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

### Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>Ombitasvir-paritaprevir-ritonavir and dasabuvir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Holkira™Pak</td>
</tr>
<tr>
<td>Dosage Form(s)</td>
<td>12.5 mg/75 mg/50 mg (ombitasvir-paritaprevir-ritonavir) and 250 mg (dasabuvir) oral tablets</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>AbbVie Corporation</td>
</tr>
</tbody>
</table>

### Submission Review

| Use Reviewed | Chronic Hepatitis C (CHC) genotype 1 infection |
| Common Drug Review (CDR) | CDR recommended to: List with criteria and conditions. Visit the CDR website for more details: [www.cadth.ca/node/88649](http://www.cadth.ca/node/88649). |

### Drug Benefit Council (DBC)

DBC now screens drug submissions under review by CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined not to be required, the Ministry’s drug coverage decision will be based on the CDEC recommendation and internal review only. The DBC screened Holkira™Pak on March 2, 2015. The DBC advised that because ombitasvir-paritaprevir-ritonavir and dasabuvir is similar to some of the other drugs for the treatment of CHC genotype 1, the Ministry may accept CDEC’s ombitasvir-paritaprevir-ritonavir and dasabuvir recommendation.

### Drug Coverage Decision

**Limited Coverage Benefit**

Access the ombitasvir-paritaprevir-ritonavir and dasabuvir criteria from [www.gov.bc.ca/pharmacarespecialauthority](http://www.gov.bc.ca/pharmacarespecialauthority).

#### Date

July 28, 2015

#### Reason(s)

Drug coverage decision is consistent with CDEC recommendation.

- Ombitasvir-paritaprevir-ritonavir and dasabuvir with or without ribavirin (RBV) reported high cure rates (based upon sustained viral response), is generally well-tolerated (compared to interferon-containing regimens) and offers a shorter duration of therapy for most patients.
- Based on the CDR pharmacoeconomic report, ombitasvir-paritaprevir-ritonavir and dasabuvir is similar in cost-effective compared to ledipasvir-sofosbuvir.
- Ombitasvir-paritaprevir-ritonavir and dasabuvir, with or without RBV, offers an alternative all-oral, interferon-free therapeutic option for CHC genotype 1 infection.

### Other Information

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:
- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. Drug Review Process and PharmaCare program for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.